Xconomy San Diego

BrainCells Depression Drug Reaches Goal

Luke Timmerman7/27/09

BrainCells Inc., the San Diego-based developer of treatments for neurological disorders, said today that its experimental drug for depression showed promising results in a clinical trial of 142 patients. The company’s drug, BCI-952, a combination of low-dose buspirone and melatonin, is designed to work differently than other depression drugs, by stimulating growth of new brain cells. The drug showed statistically significant results on some, but not all measurements of depression. Data were presented at NCDEU, a meeting co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

Links to This Post

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.